Application of hematopoietic preparation in preparation of medicine for relieving or inhibiting kidney inflammatory response
Through online pharmacology and animal experiments, the blood-generating treasure mixture promotes the secretion and synthesis of kidney EPO, downregulates TNF-α, solves the problem of regulating kidney inflammatory response, significantly improves renal function and hematopoietic ability, and provides a new direction for the development of indications.
Patent Information
- Application Number
- CN202411130168.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-08
AI Technical Summary
The existing technology has failed to effectively regulate the renal inflammatory response, especially the effect of the blood-generating agent on the renal inflammatory response has not been reported, resulting in a reduced ability of the renal synthesis of serum erythropoietin (EPO) and disordered secretion of hematopoietic factors, affecting renal function.
Through online pharmacology and animal experiments, the regulation mechanism of the blood-saccharide mixture on EPO and TNF-α in renal pathological injury is analyzed, which promotes the secretion and synthesis of renal EPO, and downregulates the expression of TNF-α to alleviate or inhibit the renal inflammatory response.
The blood treasure preparation can upregulate EPO and downregulate TNF-α, significantly improve renal function, reduce renal inflammatory response, improve the kidney's hematopoietic ability and anti-inflammatory protective effect.
Smart Images

Figure CN118903263A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of nephritis medicines, in particular to the application of Shengxuebao preparation in preparing medicines for alleviating or inhibiting kidney inflammation reaction. Background Art
[0002] Shengxuebao mixture is composed of 7 herbs: processed Polygonum multiflorum, Ligustrum lucidum, mulberry, Ecliptae, white peony root, astragalus, and Cibotium barometz. It has the effects of nourishing the liver and kidneys, invigorating Qi and producing blood. It is widely used in clinical practice to treat fatigue, dizziness and tinnitus caused by liver and kidney deficiency, deficiency of both Qi and blood; leukocytopenia caused by radio and chemotherapy, iron deficiency anemia and other diseases.
[0003] Due to liver and kidney deficiency and deficiency of both qi and blood, the kidney and bone marrow will be damaged to varying degrees, the kidney's ability to synthesize serum erythropoietin (EPO) is reduced, and the disorder of hematopoietic factor secretion leads to a decrease in the body's hematopoietic ability. In mammals, EPO produced by the kidney is essential for the production of red blood cells. After adulthood, the kidney becomes the main site of EPO production, and tumor necrosis factor-α (TNF-α) is an important inflammatory factor and negative hematopoietic factor, which is essential for hematopoiesis. Shengxuebao mixture is a commonly used blood tonic drug, which is often used for postoperative conditioning or postpartum conditioning, but the regulatory mechanism of Shengxuebao mixture for TNF-α is unclear, and the effect on renal inflammatory response has not been reported. Therefore, the present invention provides a new direction for the development of new indications for Shengxuebao mixture by studying the mechanism of action and influence between Shengxuebao mixture and TNF-α. Summary of the invention
[0004] In view of the problems existing in the prior art, the purpose of the present invention is to analyze the regulatory mechanism of Shengxuebao mixture on EPO and TNF-α of renal pathological damage and its effect on renal inflammatory response through network pharmacology and animal experiments, and to provide an application of Shengxuebao preparation in the preparation of drugs for reducing or inhibiting renal inflammatory response.
[0005] The objective of the present invention is achieved through the following technical solutions: The present invention provides application of Shengxuebao preparation in preparing medicine for alleviating or inhibiting kidney inflammation reaction.
[0006] Preferably, the Shengxuebao preparation reduces or inhibits renal inflammatory response by promoting renal EPO secretion and synthesis and downregulating TNF-α expression.
[0007] Preferably, the Shengxuebao preparation is Shengxuebao mixture or Shengxuebao granules.
[0008] Compared with the prior art, the beneficial effects of the present invention are: Through network pharmacology and animal experiments, the present invention analyzes the regulatory mechanism of Shengxuebao mixture on EPO and TNF-α of renal pathological damage in blood deficiency rat model and its effect on renal inflammatory response, and finds that Shengxuebao preparation can upregulate EPO ( P <0.05) and down-regulation of TNF-α ( P <0.05), indicating that Shengxuebao preparation can promote the secretion and synthesis of EPO in the kidney, reduce the inflammatory response of the kidney, and have a good improvement effect on renal function. BRIEF DESCRIPTION OF THE DRAWINGS
[0009] Figure 1 PPI network diagram of shared targets (A) Shared target network diagram of Shengxuebao mixture in the treatment of BDS (B) Top 20 key targets; Figure 2 This is the Shengxuebao mixture-ingredients-targets-disease network diagram; Figure 3 This is a GO functional enrichment analysis diagram; Figure 4 This is the KEGG pathway analysis diagram; Figure 5 Display 3D and 2D images of molecular docking results; Figure 6 HE staining results of kidney tissues of rats in each group, black arrows indicate glomeruli; Figure 7 is the expression of EPO and TNF-α in the serum of rats in each group; Figure 8 To investigate the effect of Shengxuebao mixture on IL-6 and IL-1β in the serum of BDS rats; Fig. 9 To investigate the effect of Shengxuebao mixture on key signaling pathway proteins in rat kidney. DETAILED DESCRIPTION
[0010] The inventive concept of the present invention will be illustrated below with reference to specific embodiments. Example
[0011] This embodiment provides the use of Shengxuebao preparation in the preparation of a drug for alleviating or inhibiting kidney inflammatory response.
[0012] In some embodiments, the Shengxuebao preparation reduces or inhibits renal inflammatory response by promoting renal EPO secretion and synthesis and downregulating TNF-α expression.
[0013] In some embodiments, the Shengxuebao preparation is Shengxuebao mixture or Shengxuebao granules.
[0014] 1. Materials 1.1 Database and software Function database Website Compound and target disease target protein name conversion TCMSPTCMIDGenecardsUniprot https: / / old.tcmsp-e.com / tcmsp.phphttps: / / bidd.group / TCMID / https: / / www.genecards.org / https: / / www.uniprot.org / Common target analysis Protein interaction network analysis Venny2.1.0STRING https: / / bioinfogp.cnb.csic.es / tools / venny / https: / / cn.string-db.org / GO and KEGG analysis DAVID6.8 https: / / david.ncifcrf.gov / Draw a bubble chart ImageGP http: / / www.ehbio.com / ImageGP / index.php / home / in dex / upsetview.html Network construction and analysis Molecular simulation and docking Cytoscape3.7.2DiscoveryStudio2020 <![CDATA[https: / / cytoscape.org / InstallationPackage ]]> 1.2 Experimental instruments instrument factory model ELISA reader Rayto RT-6100 Shaker Servicebio TSY-B Electrophoresis Apparatus Shanghai Tianneng Technology Co., Ltd. G0002 Vortex mixer USA / Scilogex MX-S Chemiluminescence imaging system Nikon Japan Nikon DS-U3 Scanner EPSON V370 Grayscale analysis software AlphaInnitech alphaEaseFC Desktop high speed refrigerated centrifuge DRAGONLAB D3024R Chemiluminescence analyzer CLINX 6300 Paper Cutter Deli No.8014 Ice Maker SIMAG SPR80 1.3 Experimental reagents and consumables Reagents factory Part Number EPO Antibody Proteintech Biotechnology Co., Ltd. 66975-1-Ig EPOR antibodies SABSignalwayAntibody #38497-1 PI3K Antibodies Affinity Biotechnology Centre Ltd AF6241 P-PI3K Antibody Affinity Biotechnology Centre Ltd AF3241 AKT Antibody Proteintech Biotechnology Co., Ltd. 60203-2-Ig P-AKT Antibody Affinity Biotechnology Centre Ltd 66444-1-Ig TNF-α Antibody Abcam Ab205587 Bcl-2 Antibody Abcam ab194583 β-actin Abcam Ab8226 Rat EPO ELISA Kit Nanjing Jiancheng Bioengineering Research Institute Co., Ltd. HO51 Rat IL-6 ELISA Kit Shenzhen Xinbosheng Biological Co., Ltd. ERC003 Rat Il-1β ELISA Kit Shenzhen Xinbosheng Biological Co., Ltd. ERC007 RIPA Lysis Buffer Beyotime P0013C 5× Protein Loading Buffer MCMBiotech WB2001 Protein molecular weight markers Proteintech PL00001 Twain 20 Solarbio TB220 ECL Proteintech PK1003 Goat anti-rabbit Abcam Ab150077 Goat anti-mouse Abcam Ab6789 Electrophoresis fluid Servicebio G2018-1L Transfer solution Servicebio G2019-1L Blood-producing mixture Tsinghua Deren Xi'an Xingfu Pharmaceutical Co., Ltd. 220823 Acetylphenylhydrazine Sinopharm Chemical Reagent Co., Ltd. A100226 Cyclophosphamide Jiangsu Hengrui Medicine Co., Ltd. 20221129 Compound donkey-hide gelatin paste Shandong Dong'e Ejiao Co., Ltd. 2211047 4% paraformaldehyde Servicebio G1101-500ML Anhydrous ethanol Sinopharm Chemical Reagent Co., Ltd. 100092693 Sodium Pentobarbital Merck 57-33-0 0.9% Sodium Chloride Shandong Chenxin Pharmaceutical Co., Ltd. E23021322
[0015] 2. Methods 2.1 Network Pharmacology Network pharmacology and molecular docking technology play an important role in the field of traditional Chinese medicine compound. It can visualize the analysis of traditional Chinese medicine compound, find the main components, key targets and pathways from the database, explore the mechanism of traditional Chinese medicine compound in an integrated and coherent manner, and finally verify it in vitro and in vivo experiments. The authenticity and scientificity of computer simulation are guaranteed.
[0016] 2.1.1 Collection and screening of active ingredients of Shengxuebao mixture TCMSP and TCMID databases were selected as websites for searching information on Chinese herbal medicine components and structures. Based on OB (oral bioavailability) and DL (drug similarity), OB ≥ 30% and DL ≥ 0.18 were determined as the key ingredient screening conditions. Shengxuebao mixture contains 7 Chinese herbs. "Prepared Polygonum multiflorum", "Astragalus", "White Peony", "Eclipta prostrata", "Ligustrum lucidum", "Mulberry", and "Ciphala cibotii" were set as keywords to collect chemical components on the TCMSP and TCMID platforms.
[0017] 2.1.2 Active ingredient target acquisition In order to standardize the names of protein targets, the protein targets corresponding to the active ingredients screened from the TCMSP database were entered into the Uniprot database at one time, the species was limited to "Homosapiens", and the format was converted to "Genesymbol" to obtain the protein target information corresponding to the ingredient.
[0018] 2.1.3 Disease target collection The GeneCards database was searched using the keyword "Blood deficiency syndrome" and the species selected was "Homo Sapiens". The collected targets were saved in an EXCEL table.
[0019] 2.1.4 Acquisition of drug-disease common targets After deleting duplicates from all ingredient targets in the Shengxuebao mixture, enter the Venny website, with ingredient targets as List1 and disease targets as List2. The intersection of the two is the common target of the drug and the disease.
[0020] 2.1.5 Construction of protein-protein interaction network The common targets of drugs and diseases were analyzed through the STRING database, and "HomoSapiens" was selected with a confidence level of 0.900 (Highestconfidence>0.9) to draw a PPI network diagram. The network visualization software Cytoscape was then used for data analysis and processing, and NetworkAnalyzer was selected to analyze the network topology characteristic values such as degree centrality (Degree) and combined score (combinedscore).
[0021] 2.1.6 Network construction, GO enrichment and KEGG pathway analysis To explore the biological process, molecular function, cellular components and related pathways of Shengxuebao mixture in the treatment of BDS. The enriched results were obtained through the DAVID database, and the results ranked in the top 20 by Count (number of genes) were selected, and the bubble chart was drawn using the ImageGP online tool. Finally, the "drug-ingredient-disease-target" network diagram was constructed in the Cytoscape software and analyzed with "NetworkAnalyzer".
[0022] 2.1.7 Molecular simulation docking The molecular structures of active compounds and protein structures of overlapping targets were downloaded from the compound database and PD website, respectively. Virtual docking of compounds and targets was performed using the DS20 program and visualized using PyMOL software. The specific analysis is as follows: First, the ligands of active compounds in Shengxuebao mixture were collected (MOL2 format) and the ligands were processed. Second, the water molecules in the original ligands and protein receptors were removed, saved in PDB format, and then converted to PDBQT format. Finally, molecular docking was performed: AutoGrid was used to set the lattice size and parameters. After the docking was completed, the binding energy was used as a reference to screen out molecules with stronger binding ability in Shengxuebao mixture. The binding energy ≤-5.0kJ / mol was used as a standard to evaluate the good binding ability of molecules with targets.
[0023] 2.2 Animal model preparation and treatment Male Sprague Dawley rats were purchased from the Experimental Animal Center of the Air Force Medical University. The standard license number for experimental animals is IACUC-20231256. The body weight is (250±20) g. The temperature and humidity during the feeding process are 22±2℃ and 50-70%, respectively. The rats are then allowed to adapt to the environment and fed for seven days before the next experiment. All animals and operations comply with the relevant regulations on experimental animal ethics and are licensed and approved by the Air Force Medical University Experimental Animal Ethics Review. The clinical medication of Shengxuebao mixture stipulates that the dosage is 15ml / time, three times a day. According to the body surface area of rats and humans, the rat dosage is 5.25ml / kg. The medium-dose group of Shengxuebao mixture is set at 2.62ml / kg, and the low-dose group is set at 1.31ml / kg. The experimental animals were divided into six groups according to the random number table method: blank group (Control), model group (Model group), Fufang ejiao Jiang group (FEJ) 6ml / kg, high dose (Shengxuebao mixture high dose, Shengxuebao mixture-H) 5.24ml / kg, middle dose group (Shengxuebao mixture middle dose, Shengxuebao mixture-M) 2.62ml / kg and low dose group (Shengxuebao mixture low dose, Shengxuebao mixture-L) 1.31ml / kg. The BDS model was established by subcutaneous injection of APH and intraperitoneal injection of CTX. The specific method was as follows: on the basis of the blank control group, the Model group, Shengxuebao mixture group and FEJ group were subcutaneously injected with APH 20mg·kg-1 on the first day, subcutaneously injected with APH 40mg·kg-1 on the fourth day, and intraperitoneally injected with CTX 25mg·kg-1 2h later. The model can be replicated by continuous injection for 4 days. The blank control group was injected with an equal volume of normal saline. Gavage was started from the first day and the drug was administered for a total of 10 days.
[0024] 2.2.1 Hematoxylin-eosin pathology test Kidney tissue was fixed with 4% paraformaldehyde, then trimmed, dehydrated, embedded, sliced, stained, and sealed. Tissue sections were observed in detail at different magnifications to detect basic pathological changes in the sections, such as congestion, necrosis, and inflammatory changes. The sections were analyzed under a light microscope and photographed with an objective lens.
[0025] (1) Embedding and sectioning: The fixed kidney slices were transferred to a dehydration box and dehydrated with 75%, 85%, 90%, 95% and 100% alcohol at different time sequences; the tissues were then immersed in xylene solution, the wax-impregnated tissues were placed in an embedding machine and cut into parallel straight lines using a small paraffin cutter.
[0026] (2) Hematoxylin-eosin staining: After hematoxylin staining for 30 minutes, rinse with running water for 1 minute, then decolorize with 1% hydrochloric acid-alcohol for 2 seconds, restain with ammonia water for 1 minute, and finally stain with eosin for 20 to 40 seconds.
[0027] (3) Dehydration and sealing: Dehydrate the slices in different concentrations of ethanol, then air dry and seal with neutral gum. Avoid bubbles during the entire operation.
[0028] (4) Photographing and analyzing results: Observe and collect images using a microscope for result analysis.
[0029] 2.2.2 ELISA method to detect the level of hematopoietic factors in serum According to the instructions of the kit, enzyme-linked immunosorbent assay (ELISA) was used to detect EPO and TNF-u, IL-6 and IL-1β in rat serum.
[0030] 2.2.3 Western blot detection of proteins related to the renal PI3K / Akt signaling pathway 1) Protein extraction: Weigh 20 mg of kidney tissue on an analytical balance, place in a 1.5 mL centrifuge tube and place on ice, prepare RIPA lysis buffer and protein phosphatase inhibitor in a ratio of 100:1, add 300 uL of the prepared lysis buffer to each sample for grinding, place on ice for lysis for 30 min, then centrifuge at 12000 rpm for 30 min in a 4° centrifuge, collect the supernatant in a new EP tube for later use.
[0031] 2) Protein quantification: Prepare the BCA quantification kit and configure the standard and AB working solution according to its instructions. First add the prepared concentration gradient standard to the 96-well plate, then add 2uL of sample, and then immediately add 200uL of working solution, incubate at 37° for 30min, measure the absorbance at 576nm and draw a standard curve. After calculating the protein concentration, add 5X protein loading buffer to each group and shake and mix, boil the protein for 10min, and place it in a -20° refrigerator after it returns to room temperature.
[0032] 3) Glue preparation: After cleaning and draining the device used for gel preparation, add double distilled water to check for leaks for 10 minutes. At the same time, prepare the separation gel and concentrated gel. First add the separation gel and let it solidify, then add the concentrated gel 40 minutes later. Immediately insert the comb vertically, and wait for 30 minutes for solidification before adding the sample.
[0033] 4) Electrophoresis and transfer: Prepare samples and protein markers, add samples and perform electrophoresis under the parameters of S1 (80V, 30min) and S2 (120V, 1.5h). After electrophoresis, soak the PVDF membrane in methanol for 30s, introduce transfer solution and transfer device, lay layers into a sandwich structure, and transfer under the conditions of (100V, 1h).
[0034] 5) Sealing and primary antibody incubation: Prepare 5% skim milk. After the membrane is transferred, take out the PVDF membrane in the clip and put it into skim milk. Slowly shake it on a shaker for 1 hour and then seal it. After sealing, wash it with PBST three times, 10 minutes each time, and incubate it with the prepared primary antibody dilutions EPO (1:1000), EPOR (1:1000), PI3K (1:500), p-PI3K (1:500), Akt (1:800), p-AKT (1:800), TNF-α (1:700), Bcl-2 (1:1000). After sealing, wash it with PBST three times, 10 minutes each time, and then incubate it with the prepared primary antibody dilutions at 4° for 8 hours.
[0035] 6) Incubation with secondary antibody: Place the primary antibody at room temperature for 30 minutes, rinse with PBST three times, 10 minutes each time, incubate with the corresponding type of antibody at room temperature for 1 hour, and then rinse with PBST three times, 10 minutes each time.
[0036] 7) Luminescence and grayscale analysis: Prepare AB luminescent liquid with a ratio of A:B=1:1, apply the luminescent liquid on the surface of the strip, and detect it through an imaging system and computer software ImageLab. After the detection, use ImageJ software for grayscale analysis.
[0037] 2.3 Statistical analysis All data were expressed as mean ± standard deviation (X ± SD) and analyzed using the statistical software Graphpad Prism 8.0. One-way ANOVA was used to analyze the significant differences among the groups. P <0.05 indicates that the results are statistically significant. P <0.01 indicated significant differences.
[0038] 3. Results 3.1 Network pharmacology results 3.1.1 Screening of active ingredients in Shengxuebao mixture The components after searching and screening in the TCMSP database are shown in Table 1. A total of 62 components were collected after screening.
[0039] Table 2-1 Chemical components screened from Shengxuebao mixture MolID MoleculeName Oral bioavailability OB (%) Drug-like DL MOL010300 dIDP(6Z,10E,14E,18E)-2,6,10,15,19,23- 41.08 0.57 MOL002372 hexamethyltetracosa-2,6,10,14,18,22-hexaene 33.55 0.42 MOL006209 Cyanin 47.42 0.76 MOL000737 Morin 46.23 0.27 MOL002773 beta-carotene 37.18 0.58 MOL000098 Quercetin 46.43 0.28 MOL000358 beta-sitosterol 36.91 0.75 MOL000422 Kaempferol 41.88 0.24 MOL004576 Taxifolin 57.84 0.27 MOL005146 LucidumosideD 48.87 0.71 MOL005147 LucidumosideD_qt 54.41 0.47 MOL005169 (20S)-24-ene-3β,20-diol-3-acetate 40.23 0.82 MOL005190 Eriodictyol 71.79 0.24 MOL005195 syringaresinoldiglucoside_qt 83.12 0.80 MOL005209 Lucidusculine 30.11 0.75 MOL005211 Olitoriside 65.45 0.23 MOL005212 Olitoriside_qt 103.23 0.78 MOL000006 Luteolin 36.16 0.25 MOL000098 Quercetin 46.43 0.28 MOL001790 Linarin 39.84 0.71 MOL001689 Acacetin 34.97 0.24 MOL002975 Butin 69.94 0.21 MOL003378 1,3,8,9-tetrahydroxybenzofurano[3,2-c]chromen-6-one 33.94 0.43 MOL003389 3'-O-Methylorobol 57.41 0.27 MOL003398 Pratensein 39.06 0.28 MOL003402 Demethylwedelolactone 72.13 0.43 MOL003404 Wedelolactone 49.6 0.48 MOL000006 Luteolin 36.16 0.25 MOL000098 Quercetin11alpha,12alpha-epoxy-3beta-23- 46.43 0.28 MOL001910 dihydroxy-30-norolean-20-en-28,12beta-olide 64.77 0.38 MOL001918 Paeoniflorgenone (3S,5R,8R,9R,10S,14S)-3,17-dihydroxy-4,4,8,10,14- 87.59 0.37 MOL001919 pentamethyl-2,3,5,6,7,9-hexahydro-1H-cyclopenta[a]phenanthrene-15,16-dione 43.56 0.53 MOL001921 Lactiflorin 49.12 0.80 MOL001924 Paeoniflorin 53.87 0.79 MOL001925 paeoniflorin_qt 68.18 0.40 MOL001928 albiflorin_qt 66.64 0.33 MOL001930 benzoylpaeoniflorine 31.27 0.75 MOL000211 Mairin 55.38 0.78 MOL000358 beta-sitosterol 36.91 0.75 MOL000359 Sitosterol 36.91 0.75 MOL000422 Kaemppherol 41.88 0.24 MOL000492 (+)-catechin 54.83 0.24 MOL000211 Mairin 55.38 0.78 MOL000239 Jaranol 50.83 0.29 MOL000296 Hederagenin(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl- 36.91 0.75 MOL000033 17-[(2R,5S)-5-propan-2-yloctan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol 36.23 0.78 MOL000354 isorhamnetin 49.6 0.31 MOL000371 3,9-di-O-methylnisoline 53.74 0.48 MOL000374 5'-hydroxyiso-muronulatol-2',5'-di-O-glucoside 41.72 0.69 MOL000378 7-O-methylisomucronulatol 74.69 0.30 MOL000379 9,10-dimethoxypterocarpan-3-O-β-D-glucoside 36.74 0.92 MOL000380 dihydro-6H-benzofuran[3,2-c]chromen-3-ol 64.26 0.42 MOL000387 Bifendate 31.1 0.67 MOL000392 formononetin 69.67 0.21 MOL000398 isoflavanone 109.99 0.3 MOL000417 Calycosin 47.75 0.24 MOL000422 kaempferol 41.88 0.24 MOL000433 FA 68.96 0.71 MOL000098 Quercetin 46.43 0.28 MOL000438 (3R)-3-(2-hydroxy-3,4-dimethoxyphenyl)chroman-7-ol 67.67 0.26 MOL000439 isomucronulatol-7,2'-di-O-glucosiole 49.28 0.62 MOL000442 1,7-Dihydroxy-3,9-dimethoxypterocarpene 39.05 0.48 3.1.2 Obtaining common targets The targets corresponding to the active ingredients of Shengxuebao mixture were deduplicated and imported into the Uniprot database to convert gene names, resulting in a total of 324 targets. 615 anemia disease targets with a score greater than 15 were screened out using the Genecards database, and 66 potential targets of Shengxuebao mixture for the treatment of BDS were obtained by taking the intersection in Venny.
[0040] 3.1.3 Results of PPI network construction of Shengxuebao mixture regulating BDS The common targets of drug components and diseases that were screened were imported into the STRING database, and a network model of protein-protein interaction and PPI enrichment was established. The degree centrality and comprehensive score of the network topology feature values were analyzed using NetworkAnalyzer. The results showed that the main targets were TNF, IL-6, AKT1, etc. Figure 1 .
[0041] 3.1.4 Network diagram of common targets of Shengxuebao mixture, compound and BDS The common targets of Shengxuebao mixture and seven medicinal materials-compound components-BDS diseases were summarized into a table and imported into Cytoscape3.7.2 software to construct a drug-compound-disease common target network diagram. Figure 2 .
[0042] 3.1.5 Analysis of enrichment of BDS predicted targets regulated by Shengxuebao mixture The DAVID online analysis tool was used to perform GO enrichment analysis on the common target proteins of Shengxuebao mixture components and BDS, including biological processes, molecular functions and cellular components. The results showed that the main biological processes regulated by Shengxuebao mixture in BDS included negative regulation of RNA polymerase II promoter transcription, apoptosis process, drug response, immune response, etc. Figure 3 The KEGG enrichment analysis of Shengxuebao mixture was performed using DAVID online analysis tools. The results showed that the mechanism of Shengxuebao mixture regulating BDS was mainly related to PI3K / Akt, HIF-1 and other signaling pathways. P <0.01 value sorting, draw the KEGG bubble diagram of the top 20 pathways, see Figure 4 .
[0043] 3.1.6 Docking of active compounds and important target molecules Nine compounds with high ranking in the "active compound-target-pathway" network, including astragaloside, 2,3,5,4'-Tetrahydroxystilbene-2-O-β-D-Glucoside, paeoniflorin, demethylwedelolactone, specnuezhenide, and isoflavanone, were selected for molecular simulation docking with the main target genes IL-6, TNF-α, and AKT1. The lower the binding energy, the more stable the conformation. Binding energy <-7.0 kcal / mol indicates that the molecule has a strong binding ability and a certain stability with the target. Ki (inhibition rate constant) is less than 10μmol / L, and the molecules have good inhibitory activity against the target. The docking results in Table 2-2 show that PI3K has a good binding score with paeoniflorin (-7.2), AKT1 has a good binding score with demethylwedeholactone (-7.3), IL6, TNF-α, and IL-1β have a good binding score with diphenylethylene glycoside (-5.2), isoflavone (-5.8), and astragaloside IV (-6.1), respectively. The results show that the 9 active ingredients have good binding activity and stability with the 5 core targets, showing good affinity. The subsequent visualization and analysis of compound-protein binding can be found in Figure 5 .
[0044] Table 3-2 Molecular docking results Target Stilbene Glycol Paeoniflorin Astragaloside IV Ligustrum lucidum Morin Wedelolide Dogwood fern Isoflavones Chrysophanol PI3K -6.5 -7.2 -8.4 -8.1 -8.2 -6.5 -8 -7.4 -8.6 AKT1 -9.2 -9.2 -10.2 -7.9 -9.9 -7.3 -8.7 -4.4 -9.7 IL-6 -5.2 -5.3 -4.7 -4.2 -4.4 -4.9 -3.8 -5.1 -5.5 TNF-α -8.7 -10.9 -7.6 -8.9 -1 -7.5 -8.4 -5.8 -10.1 IL-1β -4.7 -5.5 -6.1 -5.1 -5 -5.2 -8.1 -4.7 -5.1 3.2 Effect of Shengxuebao mixture on renal pathological damage in BDS rats HE staining was used to observe the pathological state of kidney tissue in BDS rats treated with Shengxuebao mixture. Figure 6 As shown in the figure, compared with the C group, the glomeruli of the rats in the M group were reduced, a small amount of cell necrosis appeared in the renal tissue, the number of RBCs in the renal interstitial capillaries decreased, and the glomerular capsule and tubular lumen expanded. Compared with the rats in the M group, the expansion of the glomerular capsule and tubular lumen in the Shengxuebao mixture group and the FEJ group was significantly reduced, the density of necrotic cells decreased, and the content of RBCs in the interstitial capillaries increased. The staining showed that Shengxuebao mixture could restore the renal damage caused by BDS rats.
[0045] 3.3 Effect of Shengxuebao mixture on EPO and TNF-α levels in serum of BDS rats Since blood deficiency syndrome can cause varying degrees of damage to the kidneys and bone marrow, the kidney's ability to synthesize EPO is reduced, and the secretion of hematopoietic factors is disordered, resulting in a decrease in the body's hematopoietic ability. In mammals, EPO produced by the kidneys is essential for the production of RBCs. After adulthood, the kidneys become the main site of EPO production, and TNF-α, as an important inflammatory factor and negative hematopoietic factor, is essential for hematopoiesis. Figure 7 As shown, serum EPO and TNF-α were detected by ELISA. Compared with group C, the EPO level in group M was significantly lower ( P <0.05), and TNF-α expression was significantly increased ( P <0.05, and both the Shengxuebao mixture group and the FEJ group could upregulate EPO ( P <0.05) and down-regulation of TNF-α ( P <0.05), indicating that Shengxuebao mixture can promote the secretion and synthesis of EPO in the kidney, reduce the inflammatory response of the kidney, and have a good improvement effect on renal function.
[0046] 3.4 Effect of Shengxuebao mixture on positive regulatory factors of hematopoiesis in BDS rats: IL-6 and IL-1β The connection between hematopoietic function and bone marrow hematopoiesis was described earlier. Maintaining the balance of hematopoietic factors plays an important role in restoring the body's hematopoietic function. IL-6 and IL-1β are important positive regulatory factors for hematopoiesis. By detecting these two indicators, it can be indirectly reflected whether the treatment of BDS rats with Shengxuebao mixture is related to the regulation of hematopoietic factors in the body. IL-6 is a cytokine secreted by bone marrow stromal cells, which has multiple functions such as regulating immune response, acute phase response and hematopoiesis. IL-1β is a subtype of IL-1, which can promote the proliferation of hematopoietic stem cells (HSC) and induce other cells to produce hematopoietic factors to promote hematopoiesis. Figure 8 As shown in Figure 2, ELISA was used to detect IL-6 and IL-1β in the serum of rats in each group. It was found that compared with group C, IL-6 and IL-1β in group M were significantly downregulated ( P <0.05), and the Shengxuebao mixture groups and the FEJ group could upregulate IL-6 and IL-1β ( P <0.05), which suggests that Shengxuebao mixture can improve the level of hematopoietic factors in BDS rats, thereby regulating the hematopoietic function in the body and playing a blood-tonifying role.
[0047] 3.5 Effect of Shengxuebao mixture on PI3K / Akt signaling pathway proteins in BDS rats According to the previous network pharmacology analysis results, the PI3K / Akt signaling pathway is also predicted as one of the ways to treat BDS, among which TNF-α, AKT1, etc. are predicted as important targets for the treatment of BDS. In order to verify the prediction, the expression of important targets and related targets on the PI3K / Akt signaling pathway by Shengxuebao mixture was studied. EPO, as an important hematopoietic factor in the body, can stimulate hematopoiesis with EPOR to treat anemia. At the same time, EPO also has non-hematopoietic functions such as anti-inflammatory and anti-apoptosis. Bcl-2 is an important anti-apoptotic gene; Western blot results are as follows Fig. 9 As shown, compared with group C, EPO and EPOR decreased in group M ( P <0.05), the phosphorylation levels of p-PI3K and p-Akt decreased ( P <0.05), Bcl-2 expression decreased ( P <0.05), TNF-α expression increased ( P <0.05). After treatment with Shengxuebao mixture and FEJ, the expression of EPO and EPOR proteins was significantly increased, the phosphorylation level of PI3K / Akt was increased, TNF-α was inhibited, and Bcl-2 expression was promoted. According to the above results, EPO, phosphorylated PI3K, phosphorylated AKT, and Bcl-2 were significantly increased in the Shengxuebao mixture group and the FEJ group, indicating that each therapeutic drug not only restored the expression of renal EPO, but also activated the PI3K / AKT pathway, increased the Bcl-2 content, and played an anti-apoptotic and anti-inflammatory role in renal tissue. In short, the improvement of blood deficiency symptoms by Shengxuebao mixture is related to the activation of PI3K / Akt pathway by EPO, the upregulation of Bcl-2 level, and the anti-apoptotic and anti-inflammatory effects on renal tissue.
[0048] 4. Discussion The present invention firstly observed the basic functions of rat kidneys through renal pathology. According to the previous network pharmacology analysis, the PI3K / Akt pathway was predicted to be one of the ways to treat BDS. In order to verify the prediction, the expression of important targets and related targets on the PI3K / Akt signaling pathway by Shengxuebao mixture was studied. The results showed that the renal index of rats in group M was significantly improved ( P <0.05), the kidneys also showed pathological conditions, causing different degrees of kidney damage in rats in group M. Treatment with Shengxuebao mixture showed that it could improve kidney pathology and protect kidney function; Western blot and ELISA experimental results showed that rats in group M had a resistance to the synthesis and secretion of EPO ( P <0.05, and the levels of EPO and EPOR were increased after treatment with Shengxuebao mixture and FEJ group ( P<0.05), indicating that Shengxuebao mixture can improve EPO production in rats in group M and restore blood deficiency symptoms. At the same time, hematopoietic function is inseparable from the regulation of hematopoietic factors in the body. IL-6 is a cytokine secreted by bone marrow stromal cells, which has multiple functions such as regulating immune response, acute phase response and hematopoiesis. Secondly, the expression of TNF-α in the kidneys of rats in group M increased, and the level of Bcl-2 decreased ( P <0.05), and the levels of TNF-α were reduced and the expression of Bcl-2 was increased after treatment with Shengxuebao mixture and FEJ group ( P <0.05), Shengxuebao mixture can improve the condition of rats with blood deficiency syndrome, and the mechanism may be related to promoting EPO / PI3K / Akt-mediated erythropoiesis in the kidney and reducing renal inflammatory response.
[0049] Based on mechanism research, it was found that Shengxuebao mixture can induce the expression of EPO and EPOR, activate the PI3K / Akt signaling pathway, inhibit the expression of TNF-α, promote the anti-apoptosis effect of the kidney, maintain the kidney structure, and improve the symptoms of blood deficiency, thereby playing a role in protecting renal tissue.
[0050] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. Application of Shengxuebao preparation in the preparation of drugs for alleviating or inhibiting kidney inflammatory response.
2. The use according to claim 1, characterized in that: The Shengxuebao preparation reduces or inhibits kidney inflammation by promoting kidney EPO secretion and synthesis and downregulating TNF-α expression.
3. The use according to claim 1, characterized in that: The Shengxuebao preparation is Shengxuebao mixture or Shengxuebao granules.
Citation Information
Patent Citations
Blood nourishing granules
CN1106287A
